Fortress Biotech, Inc.

Fortress Biotech, Inc.

Fortress Biotech, Inc.

Overview
Date Founded

2006

Headquarters

2 Gansevoort Street, 9th Floor, New York, NY, 10014, USA

Type of Company

Public

Employees (Worldwide)

88

Industries

Pharmaceuticals
Biotechnology

Company Description

Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. The National segment consists of National Holdings Corporation, an independent brokerage company. The company was founded on June 28, 2006 in and is headquartered in New York, NY.

Contact Data
Trying to get in touch with decision makers at Fortress Biotech, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chairman, President & Chief Executive Officer

Interim Chief Executive Officer, President

Chief Financial Officer, Treasurer & Corporate Secretary

Director & Executive Vice Chairman, Strategic Development

Senior Vice President, Biologics Operations

Chief Executive Officer-Caelum BioSciences, Inc

Chief Executive Officer, Cyprium Therapeutics, Inc

Head of Operations

Vice President-Finance & Controller

Director

Board of Directors

Chairman, President & Chief Executive Officer at Fortress Biotech, Inc.

Executive Chairman at Rgenix, Inc.

Partner at Marks Paneth LLP

President & Chief Executive Officer at TG Therapeutics, Inc.

President & Chief Executive Officer at GMF Capital LLC

Founder at Birmingham Hematology & Oncology Associates LLC

Chief Investment Officer & Senior Vice President-Treasury at Katz Group, Inc.

Paths to Fortress Biotech, Inc.
Potential Connections via
Relationship Science
You
Fortress Biotech, Inc.
Owners & Shareholders
Details Hidden

Opaleye Management's strategy for managing their fund is to actively invest, both long and short, in equity securities of biotechnology, specialty pharmaceutical and med-device companies. Typically, these are companies that are developing therapies and treatments intended for humans. The fund focuses its long investments in equity securities of companies that may not be profitable yet but whose share price may grow significantly in the near term or over a 1-2 year or longer period based on their therapeutic development and financial objectives. The fund also seeks to actively invest in stock and derivative transactions to profit from \"binary\" events, such as clinical data milestones or a US Food and Drug Administration (FDA) regulatory decision. Conversely, the fund seeks opportunities to short securities that have extended valuations relative to the marketplace. The fund generally invests in equity securities of US and foreign small and mid-cap companies.

Details Hidden

Opus Point Partners Management focuses on investments in biotechnology and healthcare companies that are developing and commercializing novel medications and diagnostic tools. Although most of the firm's healthcare investments are made through open market purchases of publicly-traded companies, each of their funds has an allocation of assets ranging from 20%-100% that is available for private investments. These investments are usually made in publicly-traded companies in the form of PIPEs and registered direct offerings, but Opus Point also considers direct investments in pre-IPO private healthcare companies. Opus Point's investments cover the broader healthcare market, but they are also interested in identifying emerging companies which are developing breakthrough medicines, medical technologies and diagnostics. The firm often takes the lead investment role in these investments.

Details Hidden

Opaleye Management's strategy for managing their fund is to actively invest, both long and short, in equity securities of biotechnology, specialty pharmaceutical and med-device companies. Typically, these are companies that are developing therapies and treatments intended for humans. The fund focuses its long investments in equity securities of companies that may not be profitable yet but whose share price may grow significantly in the near term or over a 1-2 year or longer period based on their therapeutic development and financial objectives. The fund also seeks to actively invest in stock and derivative transactions to profit from \"binary\" events, such as clinical data milestones or a US Food and Drug Administration (FDA) regulatory decision. Conversely, the fund seeks opportunities to short securities that have extended valuations relative to the marketplace. The fund generally invests in equity securities of US and foreign small and mid-cap companies.

Recent Transactions
Details Hidden

B. Riley Financial, Inc. purchases National Holdings Corp. from Fortress Biotech, Inc.

Details Hidden

Fortress Biotech, Inc. purchases National Holdings Corp.

Details Hidden

Fortress Biotech, Inc. issued Common Stock

Transaction Advisors
Investment Advisor

Advised onFortress Biotech, Inc. raised money in a private placement transaction

Investment Advisor

Advised onFortress Biotech, Inc. raised money in a private placement transaction

Legal Advisor

Advised onFortress Biotech, Inc. purchases National Holdings Corp.

Legal Advisor

Advised onFortress Biotech, Inc. purchases National Holdings Corp.

Co-Chair, Corporate Practice

Advised onFortress Biotech, Inc. purchases National Holdings Corp.

Advisors & Consultants
Publicist

Professional at 6 Degrees

Clients

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.

Key Stats and Financials As of 2018
Market Capitalization
$191M
Total Enterprise Value
$51.7M
Earnings Per Share
$-1.99
Revenue
$26.9M
TEVNet Income
-0.6x
Debt TEV
1.54x
Total Debt
$79.5M
Total Equity
$19.7M
Net Profit
$-86.5M
EBITDA
$-118M
Enterprise Value Sales
1.92x
EBITDAMargin
-438.73%
Three Year Compounded Annual Growth Rate Of Revenue
214.64%
Investments
Details Hidden

OrderGroove, Inc. provides subscription commerce solutions. It enables retailers to launch, manage and optimize programs. The firm's subscription retail platform empowers brands to provide a convenient, seamless customer experience while maximizing loyalty, recurring revenue and customer lifetime value. The company was founded by Greg Alvo in 2008 and is headquartered in New York, NY.

Details Hidden

SmartShoppr, Inc. provides a personalized shopping platforms. The firm delivers shopping services by capturing user's eCommerce footprint instantly through their email and using this information to drive a fun, personalized browsing application on the tablet. The company was founded by Saurin Shah and Ajay Subramanian in 2011 and is headquartered in Berkeley, CA.

Suppliers
Dana-Farber Cancer Institute, Inc. Biotechnology | Boston, MA

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Jubilant Life Sciences Ltd. Pharmaceuticals | Noida, UP

Jubilant Life Sciences Limited, is an integrated Pharmaceutical & Life Sciences company. As India's largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solutions provider out of India, it is constantly engaged in delivering value to its global customers through innovative technologies, products and services. The Company's strategic focus is to innovate, collaborate and accelerate the process of delivering products to the market for its customers. Today, it is well recognised as a Partner of Choice’ by leading global pharma and Life Sciences companies. The Company through its presence in India, USA, Canada, Europe and China constantly serves its customers spread across 90 countries.

City of Hope National Medical Center Government | Duarte, California

PROVIDE COMPASSIONATE MEDICAL CARE TO PEOPLE WITH CANCER AND OTHER LIFE-THREATENING DISEASES. SUPPORT RESEARCH THAT MAY BRING INNOVATIVE TREATMENTS TO PATIENTS.

Competitors
Bausch Health Cos., Inc. Pharmaceuticals - Laval, QC

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Almirall SA Pharmaceuticals - Barcelona, CT

Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.

Mayne Pharma Group Ltd. Pharmaceuticals - Salisbury, SA

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment involves in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty brands segments includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment offers manufacturing and selling of branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Fortress Biotech, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Fortress Biotech, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Fortress Biotech, Inc..